Tolebrutinib治疗复发型多发性硬化的2b期随机双盲安慰剂对照试验
主要终点为治疗12周后新发钆增强病灶数,结果显示剂量依赖性减少(p=0·03),60 mg组疗效最显著且耐受性良好。
要点
- Tolebrutinib 60 mg每日一次治疗12周使新发钆增强病灶数较安慰剂显著减少,呈剂量依赖性。
- 最常见非严重不良事件为头痛,未发生安全性相关停药或治疗相关死亡。
- 结果支持在复发型和进展型多发性硬化中开展3期临床试验。
核心结论
- 12周tolebrutinib治疗导致新发钆增强病灶呈剂量依赖性减少,60 mg剂量最有效且药物耐受性良好。
研究设计与样本
- 纳入130例18-55岁复发型多发性硬化患者,随机分配至5、15、30、60 mg每日一次四个剂量组。
主要发现
- 治疗第12周新发钆增强病灶数呈剂量依赖性减少,安慰剂组均值1·03(SD 2·50),5 mg组1·39(3·20),15 mg组0·77(1·48),30 mg组0·76(3·31),60 mg组0·13(0·43),p=0·03。
- 报告1例严重不良事件(60 mg组1例患者因多发性硬化复发住院)。
- 最常见的非严重不良事件为头痛:5 mg组1/33(3%),15 mg组3/32(9%),30 mg组1/33(3%),60 mg组4/32(13%)。
- 未发生安全性相关停药或治疗相关死亡。
关键数值与推荐
- 主要疗效终点为治疗12周后扫描(队列1第12周、队列2第16周)相对于4周前扫描的新发钆增强病灶数,与队列2安慰剂导入期4周内累积病灶比较。
- 疗效在改良意向治疗人群中分析,采用两步多重比较程序建模分析。
临床怎么用
- Tolebrutinib 60 mg每日一次可能有效减少复发型多发性硬化患者的新发脑MRI活动性病灶。
- 治疗期间需关注头痛等不良事件,但未观察到安全性相关停药。
局限性
- 样本量130例,研究周期仅16周,为2b期剂量探索试验。
- 未报告长期疗效和安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing multiple sclerosis. METHODS: We did a 16-week, phase 2b, randomised, double-blind, placebo-controlled, crossover, dose-finding trial at 40 centres (academic sites, specialty clinics, and general neurology centres) in ten countries in Europe and North America. Eligible participants were adults aged 18-55 years with diagnosed relapsing multiple sclerosis (either relapsing-remitting or relapsing secondary progressive multiple sclerosis), and one or more of the following criteria: at least one relapse within the previous year, at least two relapses within the previous 2 years, or at least one active gadolinium-enhancing brain lesion in the 6 months before screening. Exclusion criteria included a diagnosis of primary progressive multiple sclerosis or a diagnosis of secondary progressive multiple sclerosis without relapse. We used a two-step randomisation process to randomly assign eligible participants (1:1) to two cohorts, then further randomly assign participants in each cohort (1:1:1:1) to four tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched placebo (ie, identical looking tablets) for 4 weeks; cohort 2 received 4 weeks of placebo followed by 12 weeks of tolebrutinib. Participants and investigators were masked for dose and tolebrutinib-placebo administration sequence; investigators, study team members, and study participants did not have access to unmasked data. MRI scans were done at screening and every 4 weeks over 16 weeks. The primary efficacy endpoint was the number of new gadolinium-enhancing lesions detected on the scan done after 12 weeks of tolebrutinib treatment (assessed at week 12 for cohort 1 and week 16 for cohort 2), relative to the scan done 4 weeks previously, and compared with the lesions accumulated during 4 weeks of placebo run-in period in cohort 2. Efficacy data were analysed in a modified intention-to-treat population, using a two-step multiple comparison procedure with modelling analysis. Safety was assessed for all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03889639), EudraCT (2018-003927-12), and WHO (U1111-1220-0572), and has been completed. FINDINGS: Between May 14, 2019, and Jan 2, 2020, we enrolled and randomly assigned 130 participants to tolebrutinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg, and 32 to 60 mg. 129 (99%) completed the treatment regimen and 126 were included in the primary analysis. At treatment week 12, there was a dose-dependent reduction in the number of new gadolinium-enhancing lesions (mean [SD] lesions per patient: placebo, 1·03 [2·50]; 5 mg, 1·39 [3·20]; 15 mg, 0·77 [1·48]; 30 mg, 0·76 [3·31]; 60 mg, 0·13 [0·43]; p=0·03). One serious adverse event was reported (one patient in the 60 mg group was admitted to hospital because of a multiple sclerosis relapse). The most common non-serious adverse event during tolebrutinib treatment was headache (in one [3%] of 33 in the 5 mg group; three [9%] of 32 in the 15 mg group; one [3%] of 33 in the 30 mg group; and four [13%] of 32 in the 60 mg group). No safety-related discontinuations or treatment-related deaths occurred. INTERPRETATION: 12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated. Reduction of acute inflammation, combined with the potential to modulate the immune response within the CNS, provides a scientific rationale to pursue phase 3 clinical trials of tolebrutinib in patients with relapsing and progressive forms of multiple sclerosis. FUNDING: Sanofi.
引用
- Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021. PMID: 34418400. doi:10.1016/S1474-4422(21)00237-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。